Cargando…

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Undruggable proteins are a class of proteins that are often characterized by large, complex structures or functions that are difficult to interfere with using conventional drug design strategies. Targeting such undruggable targets has been considered also a great opportunity for treatment of human d...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Xin, Yu, Tingting, Li, Xiang, Zhang, Nan, Foster, Leonard J., Peng, Cheng, Huang, Wei, He, Gu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480221/
https://www.ncbi.nlm.nih.gov/pubmed/37669923
http://dx.doi.org/10.1038/s41392-023-01589-z
_version_ 1785101745696800768
author Xie, Xin
Yu, Tingting
Li, Xiang
Zhang, Nan
Foster, Leonard J.
Peng, Cheng
Huang, Wei
He, Gu
author_facet Xie, Xin
Yu, Tingting
Li, Xiang
Zhang, Nan
Foster, Leonard J.
Peng, Cheng
Huang, Wei
He, Gu
author_sort Xie, Xin
collection PubMed
description Undruggable proteins are a class of proteins that are often characterized by large, complex structures or functions that are difficult to interfere with using conventional drug design strategies. Targeting such undruggable targets has been considered also a great opportunity for treatment of human diseases and has attracted substantial efforts in the field of medicine. Therefore, in this review, we focus on the recent development of drug discovery targeting “undruggable” proteins and their application in clinic. To make this review well organized, we discuss the design strategies targeting the undruggable proteins, including covalent regulation, allosteric inhibition, protein–protein/DNA interaction inhibition, targeted proteins regulation, nucleic acid-based approach, immunotherapy and others.
format Online
Article
Text
id pubmed-10480221
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-104802212023-09-07 Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials Xie, Xin Yu, Tingting Li, Xiang Zhang, Nan Foster, Leonard J. Peng, Cheng Huang, Wei He, Gu Signal Transduct Target Ther Review Article Undruggable proteins are a class of proteins that are often characterized by large, complex structures or functions that are difficult to interfere with using conventional drug design strategies. Targeting such undruggable targets has been considered also a great opportunity for treatment of human diseases and has attracted substantial efforts in the field of medicine. Therefore, in this review, we focus on the recent development of drug discovery targeting “undruggable” proteins and their application in clinic. To make this review well organized, we discuss the design strategies targeting the undruggable proteins, including covalent regulation, allosteric inhibition, protein–protein/DNA interaction inhibition, targeted proteins regulation, nucleic acid-based approach, immunotherapy and others. Nature Publishing Group UK 2023-09-06 /pmc/articles/PMC10480221/ /pubmed/37669923 http://dx.doi.org/10.1038/s41392-023-01589-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Xie, Xin
Yu, Tingting
Li, Xiang
Zhang, Nan
Foster, Leonard J.
Peng, Cheng
Huang, Wei
He, Gu
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
title Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
title_full Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
title_fullStr Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
title_full_unstemmed Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
title_short Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
title_sort recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480221/
https://www.ncbi.nlm.nih.gov/pubmed/37669923
http://dx.doi.org/10.1038/s41392-023-01589-z
work_keys_str_mv AT xiexin recentadvancesintargetingtheundruggableproteinsfromdrugdiscoverytoclinicaltrials
AT yutingting recentadvancesintargetingtheundruggableproteinsfromdrugdiscoverytoclinicaltrials
AT lixiang recentadvancesintargetingtheundruggableproteinsfromdrugdiscoverytoclinicaltrials
AT zhangnan recentadvancesintargetingtheundruggableproteinsfromdrugdiscoverytoclinicaltrials
AT fosterleonardj recentadvancesintargetingtheundruggableproteinsfromdrugdiscoverytoclinicaltrials
AT pengcheng recentadvancesintargetingtheundruggableproteinsfromdrugdiscoverytoclinicaltrials
AT huangwei recentadvancesintargetingtheundruggableproteinsfromdrugdiscoverytoclinicaltrials
AT hegu recentadvancesintargetingtheundruggableproteinsfromdrugdiscoverytoclinicaltrials